Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Hematologic Cancers
In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy.
This activity can be accessed using the following URL: www.peerview.com/MSF
- Medical Oncologists
- BMT Specialists
- BMT Nurse Specialists
- Other Clinicians involved in the care of patients with hematologic malignancies
•Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma
•Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials
•Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events
This activity is supported by educational grants from Kite, A Gilead Company, and Novartis Pharmaceuticals Corporation.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Michael R. Bishop, MD
Director, the David and Etta Jonas Center for Cellular Therapy
Section of Hematology/Oncology
University of Chicago
Michael R. Bishop, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; CRISPR Therapeutics; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Bristol Myers Squibb.
Caron Jacobson, MD
Assistant Professor of Medicine, Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute
Caron Jacobson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; bluebird bio, Inc.; Bristol Myers Squibb/Celgene Corporation; Kite Pharma Inc.; Lonza; Nkarta, Inc.; Novartis Pharmaceuticals Corporation; and Precision Biosciences.
Michael A. Pulsipher, MD
Professor of Pediatrics
Keck School of Medicine, University of Southern California
Section Head, Transplantation and Cellular Therapy
Endowed Chair in Transplantation and Cellular Therapy Clinical Research
Children's Hospital Los Angeles Cancer and Blood Diseases Institute
Los Angeles, California
Michael A. Pulsipher, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mesoblast Ltd and Novartis Pharmaceuticals Corporation.
Other Financial or Material Support as a member of the Steering Committee for Novartis Pharmaceuticals Corporation. Study support and educational activity for Miltenyi Biotec. Study support for Adaptive Biotechnologies.
Anita D’Souza, MD
Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.
Paige Davies, PhD
PVI, PeerView Institute for Medical Education
Paige Davies, PhD, has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.